Chronic Kidney Disease, Acid-Base & Nephrolithiasis — Clinical Compendium

CKD Mineral Bone Disease

Phosphate retention + ↓ renal 1α-hydroxylase (calcitriol) → hypocalcemia → secondary hyperparathyroidism → osteitis fibrosa cystica (subperiosteal resorption).

Anemia of CKD Protocol

Normocytic anemia from EPO deficiency in peritubular interstitial cells; replete iron FIRST, then give epoetin/darbepoetin to target Hgb 10–11.5 g/dL.

Urine Anion Gap (UAG)

UAG = (U_Na + U_K) − U_Cl; Negative UAG in diarrhea (intact renal NH₄Cl excretion) vs. Positive UAG in Renal Tubular Acidosis (impaired NH₄⁺).

RTA Types 1, 2, and 4

Type 1 (Distal): pH > 5.5, hypokalemia, CaPO₄ stones; Type 2 (Proximal): pH < 5.5, Fanconi; Type 4: Hyperkalemia (hypoaldosteronism).

Winters Formula

Expected PaCO₂ = 1.5 × [HCO₃⁻] + 8 ± 2; Salicylate overdose causes early respiratory alkalosis + late high-AG metabolic acidosis.

Metabolic Alkalosis Urine Cl

Saline-responsive (U_Cl < 20 mEq/L): vomiting, NG suction, prior diuretics. Saline-resistant (U_Cl > 20 mEq/L): Conn, Cushing, Bartter, Gitelman.

ADPKD vs. ARPKD

ADPKD: PKD1 (chr 16) / PKD2, adults, berry aneurysms, MVP, hepatic cysts, Rx: Tolvaptan. ARPKD: PKHD1, neonates, Potter sequence, hepatic fibrosis.

Clear Cell RCC Hallmarks

Proximal tubule origin, VHL (chr 3p) deletion (↑ HIF → ↑ VEGF/PDGF); hematuria + flank mass + left-sided varicocele; paraneoplastic EPO, PTHrP, ACTH, renin.

Stepwise Acid-Base Interpretation Guide

Chronic Kidney Disease (CKD, defined as eGFR <60 mL/min/1.73 m² or structural kidney damage/albuminuria for ≥3 months) and Renal Tubular Acidosis (RTA) disrupt systemic acid-base, potassium, and mineral bone homeostasis. Integrating the Urine Anion Gap (Urine Na⁺ + Urine K⁺ minus Urine Cl^-), minimum urinary pH (<5.5 vs. >5.5), and serum potassium concentration differentiates Type 1 (Distal), Type 2 (Proximal), and Type 4 (Hyporeninemic Hypoaldosteronism) Renal Tubular Acidosis.

Disorder	Primary Abnormality	Compensatory Response	High-Yield Etiologies
High Anion Gap Metabolic Acidosis (HAGMA)	Low HCO3- (< 24) with Anion Gap > 12 [Na - (Cl + HCO3)]	Respiratory hyperventilation (Winter's: PaCO2 = 1.5 × HCO3 + 8 ± 2)	GOLD MARK: Glycols, Oxoproline, L-lactate, D-lactate, Methanol, Aspirin/salicylates, Renal failure (uremia), Ketoacidosis (DKA, starvation)
Normal Anion Gap (Hyperchloremic) Acidosis	Low HCO3- with normal AG (≤ 12); high serum chloride	Respiratory hyperventilation	HARDASS: Hyperalimentation, Acetazolamide, Renal tubular acidosis (RTA 1, 2, 4), Diarrhea (loss of bicarb), Spironolactone
Metabolic Alkalosis	High HCO3- (> 28) with high arterial pH (> 7.45)	Hypoventilation (PaCO2 rises ~0.7 mmHg per 1 mEq/L rise in HCO3-)	Saline-responsive (Urine Cl < 20): Vomiting, nasogastric suction, loop/thiazide diuretics. Saline-resistant (Urine Cl > 20): Primary hyperaldosteronism, Cushing syndrome

Differentiating the Three Renal Tubular Acidoses (RTA Types 1, 2 & 4): Urine pH, Potassium & Nephrolithiasis

All three Renal Tubular Acidoses (RTAs) produce a Normal Anion Gap (Hyperchloremic) Metabolic Acidosis (NAGMA) with a POSITIVE Urine Anion Gap (reflecting impaired renal NH₄⁺Cl^- excretion, unlike diarrhea which has a negative Urine AG), and are separated immediately by Serum Potassium and Urine pH: (1) Type 1 (Distal) RTA is a defect in the α-intercalated cells of the collecting duct, which cannot secrete H⁺ into the lumen via the apical H⁺-ATPase or H⁺/K⁺-ATPase; consequently, Urine pH is ALWAYS >5.5 despite severe systemic acidemia, Serum K⁺ is LOW (Hypokalemia), and chronic bone buffering of acid combined with alkaline urine and hypocitraturia causes bilateral Nephrocalcinosis and Calcium Phosphate kidney stones! Classic causes of Type 1 RTA include Sjögren syndrome, SLE, Amphotericin B toxicity, analgesic nephropathy, and congenital obstruction (treat with oral Potassium Citrate). (2) Type 2 (Proximal) RTA is a defect in proximal convoluted tubule bicarbonate (HCO₃^-) reabsorption (carbonic anhydrase defect); once serum HCO₃^- falls below the reduced proximal reclamation threshold (~14–18 mEq/L), the intact distal collecting duct successfully acidifies the urine, so Urine pH is <5.5, Serum K⁺ is LOW (Hypokalemia), and bone demineralization/rickets occurs without calcium phosphate stones. Type 2 RTA is commonly part of generalized proximal tubular dysfunction (Fanconi Syndrome: glycosuria with normal blood glucose, aminoaciduria, phosphaturia, and uricosuria) caused by Multiple Myeloma light chains, Wilson disease, Cystinosis, Tenofovir, Ifosfamide, Expired Tetracyclines, Acetazolamide, or Topiramate. (3) Type 4 RTA is the ONLY RTA that presents with HYPERKALEMIA (and Urine pH <5.5), caused by aldosterone deficiency or resistance (Hyporeninemic Hypoaldosteronism) in Diabetic Nephropathy, ACEi/ARBs, Spironolactone, TMP-SMX, or NSAIDs (hyperkalemia directly inhibits proximal tubular NH₃ synthesis, impairing acid excretion; treat with Fludrocortisone or Loop Diuretics + dietary K⁺ restriction).

CKD Mineral & Bone Disorder (Renal Osteodystrophy Cascade) & Anemia of CKD (EPO / Iron Targets)

As Chronic Kidney Disease progresses to Stage 4–5 (eGFR <30 mL/min/1.73 m²), two systemic endocrine cascades must be actively managed: (1) CKD-Mineral and Bone Disorder (Secondary → Tertiary Hyperparathyroidism and Renal Osteodystrophy): the chronological sequence begins with impaired renal phosphate excretion (Hyperphosphatemia) (which stimulates osteocyte FGF-23 secretion) AND loss of proximal tubular 1α-hydroxylase activity (decreased active 1,25-(OH)₂ Vitamin D [Calcitriol]). Elevated serum phosphate chelates ionized Ca²⁺ while low calcitriol reduces intestinal Ca²⁺ absorption, producing Hypocalcemia. Both hypocalcemia and hyperphosphatemia stimulate the parathyroid glands to develop diffuse chief-cell hyperplasia and secrete massive Parathyroid Hormone (Secondary Hyperparathyroidism: HIGH PTH, LOW/Normal Ca²⁺, HIGH Phosphate), which resorbs bone to cause Osteitis Fibrosa Cystica (subperiosteal bone resorption of the radial aspect of the middle phalanges, 'salt-and-pepper' skull, and osteoclast-filled 'brown tumors'). If longstanding secondary hyperparathyroidism goes untreated, parathyroid chief cells undergo autonomous clonal nodular transformation (Tertiary Hyperparathyroidism: VERY HIGH PTH + HIGH Ca²⁺ + HIGH Phosphate, requiring parathyroidectomy). Treat CKD-MBD with dietary phosphate restriction, non-calcium oral phosphate binders (Sevelamer) or calcium acetate, Calcitriol (active vitamin D), and the calcimimetic Cinacalcet (which sensitizes the parathyroid Ca²⁺-sensing receptor). (2) Normocytic Anemia of CKD results from loss of peritubular interstitial fibroblast Erythropoietin (EPO) synthesis; before initiating recombinant Erythropoiesis-Stimulating Agents (Epoetin alfa / Darbepoetin), always replete Iron stores first (Ferritin >100–200 ng/mL, TSAT >20%) and target a conservative Hemoglobin of 10.0 to 11.5 g/dL (targeting Hb >13 g/dL with EPO increases hypertension, stroke, and thromboembolism mortality!).

Nephrolithiasis: Crystal Morphology & Management

Nephrolithiasis (renal colic presenting with sudden, severe, colicky flank pain radiating to the ipsilateral groin/testicle/labia with gross or microscopic hematuria and inability to sit still) is diagnosed with Non-Contrast Helical CT of the Abdomen and Pelvis (or Renal Ultrasound in pregnant women and children). Identifying the exact stone composition via radiodensity on KUB radiograph, urinary pH, and urine microscopy crystal morphology guides targeted medical prevention.

Stone Composition	X-Ray & CT Appearance	Microscopic Crystal Shape & Urine pH	Treatment & Prevention Strategy
Calcium Oxalate (75–80%)	Radiopaque on X-ray; white on CT	Envelope-shaped or dumb-bell; independent of pH; hypercalciuria / ethylene glycol	Hydration, thiazide diuretics (decrease urine calcium), low-sodium diet; do NOT restrict dietary calcium (calcium binds oxalate in gut)
Struvite (Ammonium Magnesium Phosphate)	Radiopaque; forms massive staghorn calculi in renal pelvis	'Coffin-lid' crystals; alkaline urine (pH > 7.0) due to urease-positive organisms (Proteus mirabilis, Klebsiella)	Complete surgical eradication (percutaneous nephrolithotomy) + antimicrobial therapy; stone acts as foreign bacterial nidus
Uric Acid (5–10%)	Radiolucent on X-ray; visible on non-contrast CT	Rhomboid or needle-shaped; acidic urine (pH < 5.5); gout, high cell turnover (tumor lysis)	Urine alkalinization with potassium citrate; Allopurinol / Febuxostat for hyperuricemia
Cystine (1–2%)	Faintly radiopaque on X-ray	Hexagonal crystals; positive sodium cyanide-nitroprusside test; autosomal recessive defect in COLA transporter	High hydration (> 3–4 L/day), urine alkalinization (potassium citrate); chelating agents (tiopronin, penicillamine)

Radiopaque vs. Radiolucent Stones, Crystal Morphology & Enteric Hyperoxaluria (Crohn Disease) Paradox

Memorize the composition, X-ray visibility, urinary pH, and crystal shapes of the four major renal calculi: (1) Calcium Stones (Calcium Oxalate [80%] > Calcium Phosphate) are brightly RADIOPAQUE on X-ray/CT, with Calcium Oxalate showing envelope-shaped (dihydrate) or dumbbell-shaped (monohydrate) crystals (pH-independent) and Calcium Phosphate showing wedge-shaped prisms in alkaline urine (pH >6.0, associated with Type 1 Distal RTA and primary hyperparathyroidism). Most calcium oxalate stones result from Idiopathic Hypercalciuria (with NORMAL serum calcium!), ethylene glycol toxicity, Vitamin C abuse, or Enteric Hyperoxaluria in Crohn Disease / Ileal Resection / Roux-en-Y Gastric Bypass: normally, intraluminal dietary calcium binds dietary oxalate in the gut to form insoluble calcium oxalate excreted in stool; in fat malabsorption, unabsorbed intraluminal free fatty acids bind calcium instead ('saponification'), leaving unbound oxalate to be hyperabsorbed in the colon and excreted in urine! (2) Struvite Stones (Magnesium Ammonium Phosphate, 10%–15%) are moderately RADIOPAQUE, form giant branching 'Staghorn Calculi' filling the renal pelvis and calyces, display 'coffin-lid' rectangular prism crystals, and occur exclusively in ALKALINE urine (pH >7.5–8.0) infected by urease-producing bacteria (Proteus mirabilis, Klebsiella, Pseudomonas, Staphylococcus saprophyticus—NEVER E. coli!), where bacterial urease cleaves urea into ammonia (NH₃ + H₂O → NH₄⁺ + OH^-). (3) Uric Acid Stones (5%–10%) are completely RADIOLUCENT on plain KUB X-ray (visible on non-contrast CT or as filling defects), display rhomboid or rosette crystals, and form in ACIDIC urine (pH <5.5) in patients with gout, tumor lysis syndrome/leukemia, or chronic diarrheal volume/bicarbonate loss. (4) Cystine Stones (1%) are faintly radiopaque, form staghorn stones in children/young adults with autosomal recessive Cystinuria (defect in proximal tubular COLA transporter for Cystine, Ornithine, Lysine, Arginine), display pathognomonic flat HEXAGONAL crystals in acidic urine, and turn purple on the urinary Cyanide-Nitroprusside test.

Acute Expulsive Therapy (Tamsulosin <10 mm), Surgical Decompression for Obstructed Pyelonephritis & Stone Prevention

Acute management of ureterolithiasis depends on stone diameter and the presence of infection/obstruction: CRITICAL EMERGENCY RULE: If a patient with an obstructing ureteral stone presents with fever, leukocytosis, pyuria, or hemodynamic instability (Obstructive Pyelonephritis / Urosepsis)—or anuria/solitary kidney with AKI—medical expulsive therapy and shockwave lithotripsy are CONTRAINDICATED; the patient requires IMMEDIATE URGENT DECOMPRESSION via Cystoscopic Retrograde Ureteral Stent placement or Percutaneous Nephrostomy Tube plus broad-spectrum IV antibiotics! For uncomplicated, non-infected stones: stones ≤5 mm pass spontaneously in >80% of cases with hydration and NSAID analgesia (Ketorolac) (NSAIDs are superior to opioids because they decrease ureteral smooth muscle spasm and local prostaglandin-mediated edema); stones 5 to 10 mm in the distal ureter are treated with Medical Expulsive Therapy using the alpha-1A antagonist Tamsulosin (or Nifedipine) for up to 4 weeks; and stones >10 mm (or stones failing to pass after 4–6 weeks) require urologic intervention via Ureteroscopy with Laser Lithotripsy or Extracorporeal Shock Wave Lithotripsy (ESWL) (staghorn calculi require Percutaneous Nephrolithotomy [PCNL]). For long-term prevention of recurrent Calcium Oxalate stones, prescribe high fluid intake (>2.5 L/day), a NORMAL dietary calcium intake (never restrict dietary calcium, as low gut calcium increases colonic oxalate absorption!), low sodium/animal protein diet, Thiazide Diuretics (hydrochlorothiazide/chlorthalidone, which stimulate distal convoluted tubule Ca²⁺ reabsorption to cure idiopathic hypercalciuria), and Potassium Citrate. Uric acid stones are dissolved medically by alkalinizing the urine to pH 6.5–7.0 with Oral Potassium Citrate (plus Allopurinol), and Cystine stones are treated with high hydration, Potassium Citrate alkalinization (pH >7.5), and Tiopronin or D-Penicillamine (thiol chelators).

Chronic Kidney Disease Staging, Mineral & Bone Disorder (Renal Osteodystrophy) & Anemia of CKD

Chronic Kidney Disease (CKD) is defined by abnormalities of kidney structure (such as albuminuria ≥ 30 mg/g or polycystic morphology) or function (estimated GFR < 60 mL/min/1.73 m²) persisting for ≥ 3 months. Diabetic nephropathy (non-enzymatic glycosylation of efferent arterioles causing hyperfiltration, mesangial expansion, and Kimmelstiel-Wilson nodular glomerulosclerosis) and hypertensive nephrosclerosis are the two leading causes of end-stage renal disease (ESRD). As functional nephron mass declines below a GFR of 45–60 mL/min/1.73 m², the kidneys lose their endocrine and homeostatic capacity, precipitating two universal systemic complications: CKD-Mineral and Bone Disorder (CKD-MBD / Renal Osteodystrophy) and normocytic Anemia of CKD.

Condition	Serum Calcium (Ca2+)	Serum Phosphate (PO43-)	Alkaline Phosphatase (ALP)	Intact PTH & Calcitriol	First-Line Therapy
Secondary Hyperparathyroidism (CKD Stage 3–5)	Low or Low-Normal	High (Hyperphosphatemia)	Elevated (high bone turnover)	Markedly Elevated PTH; Low 1,25-(OH)₂D₃	Sevelamer (phosphate binder) + Calcitriol + Cinacalcet
Tertiary Hyperparathyroidism (Longstanding ESRD)	High (Autonomous Hypercalcemia)	High	Markedly Elevated	Extremely High PTH (autonomous hyperplasia)	Subtotal (3.5-gland) or total parathyroidectomy with autotransplantation
Primary Hyperparathyroidism (Adenoma)	High	Low (PTH inhibits NaPi-IIa/c in PCT)	Normal to High	Elevated or inappropriately normal PTH; High 1,25-(OH)₂D₃	Parathyroidectomy (if symptomatic, Ca > 1 mg/dL above ULN, T-score ≤ −2.5, GFR < 60, age < 50)
Vitamin D Deficiency (Osteomalacia)	Low or Low-Normal	Low (secondary PTH causes phosphaturia)	Elevated	Elevated PTH (secondary); Low 25-OH Vitamin D	Ergocalciferol (Vitamin D₂) or Cholecalciferol (Vitamin D₃) repletion
Adynamic Bone Disease (Over-suppressed PTH in ESRD)	Normal to High	Normal to High	Low or Normal	Inappropriately Low PTH (excess vitamin D / calcium binders)	Reduce or hold calcitriol and switch calcium-based binders to sevelamer

Renal Tubular Acid-Base Handling and Countercurrent Exchange Schematic — **Nephron Acid-Base & Electrolyte Transport Plate:** Segmental nephron physiology illustrating proximal convoluted tubule bicarbonate reclamation (85%) via carbonic anhydrase, thick ascending limb countercurrent multiplication, and collecting duct alpha-intercalated cell proton secretion and ammonia trapping. View Full Resolution

KDIGO GFR & Albuminuria Staging & Renoprotective Pharmacotherapy

KDIGO classifies CKD across six GFR categories: G1 (≥ 90 with kidney damage), G2 (60–89), G3a (45–59), G3b (30–44), G4 (15–29, severe reduction requiring dialysis access planning), and G5 (< 15 mL/min/1.73 m², kidney failure / ESRD), paired with three albuminuria categories: A1 (< 30 mg/g), A2 (30–300 mg/g, moderately increased / microalbuminuria), and A3 (> 300 mg/g, severely increased / macroalbuminuria). Two pharmacological classes independently slow CKD progression by reducing intraglomerular filtration pressure: ACE inhibitors (lisinopril) or ARBs (losartan), which block angiotensin II-mediated efferent arteriolar vasoconstriction, and SGLT2 inhibitors (dapagliflozin, empagliflozin), which restore proximal NaCl delivery to the macula densa and activate tubuloglomerular feedback to constrict the afferent arteriole. A rise in serum creatinine up to 30% after starting an ACEi/ARB or SGLT2i is expected hemodynamic protection; only discontinue if creatinine rises > 30% (which suggests bilateral renal artery stenosis) or if refractory hyperkalemia (> 5.5 mEq/L) develops.

Renal Osteodystrophy (Osteitis Fibrosa Cystica) Pathophysiology & Stepwise Management

The pathogenesis of secondary hyperparathyroidism in CKD begins with impaired glomerular filtration of phosphate (hyperphosphatemia) and rising fibroblast growth factor 23 (FGF-23). Concurrently, loss of proximal renal tubular mass and FGF-23 suppression markedly decrease 1α-hydroxylase activity, halting the conversion of 25-hydroxyvitamin D into active 1,25-dihydroxyvitamin D (calcitriol). Calcitriol deficiency impairs intestinal calcium absorption, while excess serum phosphate complexes directly with free ionized calcium, producing hypocalcemia. Both hypocalcemia and hyperphosphatemia stimulate the parathyroid chief cells to secrete massive quantities of PTH (secondary hyperparathyroidism). Chronically elevated PTH drives high-turnover bone disease (osteitis fibrosa cystica), characterized radiographically by subperiosteal bone resorption along the radial aspect of the middle phalanges, 'rugby-jersey' vertebral spines, 'salt-and-pepper' skull deossification, and brown tumors (collections of osteoclast giant cells mixed with hemosiderin pigment). After years of autonomous stimulation, parathyroid hyperplasia becomes refractory to calcium feedback, resulting in tertiary hyperparathyroidism (spontaneous severe hypercalcemia + very high PTH) and calciphylaxis (medial arteriolar calcification and painful necrotic skin ulcers). Management requires dietary phosphate restriction, non-calcium oral phosphate binders (sevelamer, lanthanum) with meals, active vitamin D analogs (calcitriol, paricalcitol), and calcimimetics (cinacalcet, which allosterically activates the parathyroid calcium-sensing receptor [CaSR]).

Anemia of CKD (EPO Deficiency, Iron Repletion First, Target Hgb 10–11.5 g/dL) & Uremic Platelet Dysfunction

Peritubular interstitial fibroblasts (type I interstitial cells) in the renal cortex sense tissue hypoxia via HIF-2α and synthesize erythropoietin (EPO). In Stage G3b–G5 CKD, fibrotic destruction of these cells produces a normocytic, normochromic hypoproliferative anemia with an inappropriately low reticulocyte count. Before initiating recombinant erythropoiesis-stimulating agents (ESAs: epoetin alfa or darbepoetin alfa), clinicians must always evaluate and replete iron stores first (target transferrin saturation [TSAT] ≥ 20–30% and serum ferritin ≥ 100–500 ng/mL, often requiring IV iron sucrose in hemodialysis patients due to hepcidin-mediated block of gut ferroportin). Functional iron deficiency is the #1 cause of ESA hyporesponsiveness. When prescribing epoetin/darbepoetin, titrate to a strict target hemoglobin of 10.0 to 11.5 g/dL; targeting normal hemoglobin (> 13 g/dL) significantly increases the risk of hypertension, stroke, myocardial infarction, and vascular access thrombosis. Separately, severe uremia causes mucosal bleeding despite a normal platelet count, PT, and aPTT because guanidinosuccinic acid impairs platelet aggregation and adhesion (prolonged bleeding time); acute treatment is desmopressin (DDAVP), which releases endothelial vWF/Factor VIII stores, alongside emergent hemodialysis.

High vs. Normal Anion Gap Metabolic Acidosis, Urine Anion Gap & Renal Tubular Acidosis (Types 1, 2, 4)

Every metabolic acidosis (arterial pH < 7.35 with serum HCO₃⁻ < 24 mEq/L) is immediately classified by calculating the serum Anion Gap: AG = [Na⁺] − ([Cl⁻] + [HCO₃⁻]) (normal baseline = 8–12 mEq/L, corrected downward by 2.5 mEq/L for every 1 g/dL drop in serum albumin below 4.0 g/dL). When unmeasured organic or inorganic acid anions titrate bicarbonate, the anion gap widens (> 12 mEq/L, HAGMA). When bicarbonate is directly lost from the gastrointestinal tract or kidneys and replaced millimeter-for-millimeter by renal chloride reabsorption, a Normal Anion Gap (Hyperchloremic) Metabolic Acidosis (NAGMA) results, which is further dissected using the Urine Anion Gap (UAG) and urine pH.

Feature	Distal RTA (Type 1)	Proximal RTA (Type 2)	Hyperkalemic RTA (Type 4)	Secretory Diarrhea / Laxatives
Nephron Segment & Defect	Collecting duct α-intercalated cell failure to secrete H⁺	Proximal convoluted tubule (PCT) failure to reabsorb HCO₃⁻	Collecting duct principal cell hypoaldosteronism / resistance	Normal nephron; GI loss of HCO₃⁻ and K⁺
Urine Anion Gap (UAG)	Positive (> 0) (impaired NH₄Cl)	Positive or slightly negative depending on HCO₃⁻ load	Positive (> 0) (K⁺ inhibits ammoniagenesis)	Strongly Negative (< −20) (high renal NH₄Cl excretion)
Urine pH (During Acidemia)	Always > 5.5 (unable to acidify urine)	< 5.5 (once serum HCO₃⁻ drops below 15 mEq/L; > 5.5 if given bicarb)	< 5.5 (distal H⁺ pump intact, but lacks NH₃ buffer)	< 5.5 to 6.0 (normal distal acidification)
Serum Potassium (K+)	Low (Hypokalemia)	Low (Hypokalemia)	High (Hyperkalemia)	Low (Hypokalemia)
High-Yield Etiologies	Sjögren syndrome, SLE, Amphotericin B, lithium, congenital	Fanconi syndrome (Multiple myeloma, Tenofovir, Wilson, Lead), Acetazolamide	Diabetic nephropathy (hyporeninemic), ACEi/ARB, Spironolactone, TMP-SMX	VIPoma, cholera, villous adenoma, Crohn disease, laxative abuse
Complications & Treatment	Calcium phosphate stones & nephrocalcinosis; Rx: Oral potassium citrate	Hypophosphatemic rickets / osteomalacia (rare stones); Rx: High-dose K-citrate + thiazide	Cardiac arrhythmias from hyperkalemia; Rx: Fludrocortisone, furosemide, patiromer	Volume depletion; Rx: Isotonic IV fluids + potassium/bicarbonate repletion

Abdominal Radiograph of Radiopaque Renal Calculus — **Radiopaque Nephrolithiasis KUB Plate:** Plain abdominal radiograph demonstrating a dense radiopaque calcium-containing calculus projected over the renal pelvis and proximal ureter. View Full Resolution

High Anion Gap Metabolic Acidosis (MUDPILES / GOLD MARK) & Osmolar Gap

High Anion Gap Metabolic Acidosis arises from the accumulation of non-chloride-containing acids (MUDPILES): Methanol (formic acid causing optic disc hyperemia and blindness), Uremia (retained sulfates, phosphates, urate in ESRD), Diabetic/Alcoholic/Starvation Ketoacidosis (β-hydroxybutyrate and acetoacetate), Propylene glycol (IV lorazepam/diazepam solvent) or Pyroglutamic acid (5-oxoproline from chronic acetaminophen use in malnourished women), Iron tablets or Isoniazid (seizures + lactic acidosis), Lactic acidosis (Type A tissue hypoxia/shock/sepsis/mesenteric ischemia; Type B metformin, linezolid, cyanide, thiamine deficiency), Ethylene glycol (glycolic and oxalic acid causing envelope-shaped calcium oxalate monohydrate crystals, cranial nerve palsies, and acute tubular necrosis), and Salicylates (aspirin). In suspected toxic alcohol ingestion, calculate the Serum Osmolar Gap = Measured Osmolality − [2 × Na⁺ + (Glucose / 18) + (BUN / 2.8) + (Ethanol / 4.6)]; an osmolar gap > 10 mOsm/kg paired with HAGMA mandates immediate fomepizole (competitive alcohol dehydrogenase inhibitor) ± hemodialysis.

Normal Anion Gap Acidosis (HARDASS) & Urine Anion Gap (UAG = UNa + UK - UCl)

Normal Anion Gap (Hyperchloremic) Metabolic Acidosis is caused by (HARDASS): Hyperalimentation (TPN), Acetazolamide (carbonic anhydrase inhibitor), Renal Tubular Acidosis (Types 1, 2, 4), Diarrhea (or high-output ileostomy/pancreatic/biliary fistula), Addison disease (adrenal insufficiency), Spironolactone, and Saline infusion (large-volume 0.9% NaCl). To distinguish extrarenal GI bicarbonate loss (diarrhea) from impaired renal acid excretion (RTA), calculate the Urine Anion Gap: UAG = (U_Na + U_K) − U_Cl. Because ammonium (NH₄⁺) is the major unmeasured urinary cation excreted with chloride (NH₄Cl) during acidemia, UAG serves as an inverse surrogate for urinary NH₄⁺ excretion. In diarrhea (or laxative abuse), healthy kidneys appropriately upregulate NH₄Cl excretion, making U_Cl > (U_Na + U_K) and yielding a NEGATIVE Urine Anion Gap (< −20 mEq/L, 'neGUTive'). Conversely, in Renal Tubular Acidosis, the kidneys fail to excrete NH₄Cl, leaving U_Cl low and yielding a POSITIVE Urine Anion Gap (> 0 mEq/L).

Renal Tubular Acidosis Discriminator: Distal (Type 1) vs. Proximal (Type 2) vs. Hyperkalemic (Type 4)

Distal RTA (Type 1) is a defect in α-intercalated cells of the collecting duct, which cannot secrete H⁺ via apical H⁺-ATPase or H⁺/K⁺-ATPase. Consequently, the urine cannot be acidified regardless of systemic acidemia, yielding a persistently alkaline urine pH > 5.5 and hypokalemia. Chronic acidemia leaches calcium and phosphate from bone, while alkaline urine and hypocitraturia precipitate bilateral calcium phosphate kidney stones and nephrocalcinosis. Etiologies include Sjögren syndrome, SLE, amphotericin B toxicity, and analgesic nephropathy; treat with oral potassium citrate. Proximal RTA (Type 2) is a defect in proximal convoluted tubule (PCT) HCO₃⁻ reabsorption, reducing the renal bicarbonate threshold from 24 to ~15 mEq/L. Once serum HCO₃⁻ falls below 15 mEq/L, distal α-intercalated cells reclaim all remaining filtered bicarbonate and acidify the urine normally (urine pH < 5.5), accompanied by hypokalemia and osteomalacia/rickets (no kidney stones because urinary citrate is preserved). Etiologies include Fanconi syndrome (multiple myeloma light chains, Wilson disease, cystinosis, expired tetracyclines, tenofovir, lead) and acetazolamide. Hyperkalemic RTA (Type 4) results from aldosterone deficiency or collecting duct aldosterone resistance. Hyperkalemia directly inhibits proximal ammoniagenesis (NH₃ synthesis from glutamine); patients exhibit hyperkalemia, mild NAGMA, and urine pH < 5.5. Etiologies include diabetic hyporeninemic hypoaldosteronism, ACEi/ARBs, spironolactone/eplerenone, trimethoprim, pentamidine, and NSAIDs; treat with fludrocortisone or loop/thiazide diuretics.

Winters Formula, Delta-Delta Ratio & Mixed Acid-Base Disorders Worked Scenarios

Board vignettes frequently present complex patients with two or three simultaneous acid-base disturbances—such as aspirin overdose, septic shock in a patient with chronic COPD, or diabetic ketoacidosis accompanied by intractable vomiting. Solving these vignettes requires applying Winters formula to verify whether respiratory compensation is appropriate, followed by calculating the Delta-Delta (ΔAG / ΔHCO₃⁻) ratio to uncover hidden metabolic disorders, and using urine chloride (U_Cl) to classify metabolic alkalosis.

Clinical Vignette / Syndrome	Arterial pH	PaCO2 vs. Winters Prediction	Serum HCO3- & Anion Gap	Urine Chloride / Specific Clue & Acid-Base Diagnosis
Aspirin (Salicylate) Toxicity (Adult, 6h post-ingestion)	7.38–7.45 (Normal or high)	PaCO₂ LOWER than Winters expected	Low HCO₃⁻ (< 15); High AG (> 20)	Tinnitus, tachypnea, fever; Mixed Respiratory Alkalosis + High-AG Metabolic Acidosis; Rx: IV NaHCO₃
Severe COPD + Septic Shock (Lactic Acidosis)	< 7.15 (Severely acidemic)	PaCO₂ HIGHER than Winters expected	Low HCO₃⁻; High AG (lactate > 4)	Mixed High-AG Metabolic Acidosis + Respiratory Acidosis
Gastric Outlet Obstruction / Bulimia / NG Suction	> 7.48 (Alkalemic)	Compensatory rise (~0.7 × ΔHCO₃⁻)	High HCO₃⁻ (> 32); Normal AG; Low K⁺/Cl⁻	U_Cl < 20 mEq/L (Saline-responsive); Rx: 0.9% NaCl + KCl
Conn Syndrome (Primary Hyperaldosteronism)	> 7.45 (Alkalemic)	Compensatory mild hypercapnia	High HCO₃⁻; Low K⁺; High-normal Na⁺	U_Cl > 20 mEq/L (Saline-resistant) + Hypertension; High Aldosterone/Renin ratio; Rx: Spironolactone / adrenalectomy
Bartter Syndrome	> 7.45 (Alkalemic)	Compensatory mild hypercapnia	High HCO₃⁻; Low K⁺	U_Cl > 20 + Normotensive + Hypercalciuria (TAL NKCC2 defect = 'loop diuretic')
Gitelman Syndrome	> 7.45 (Alkalemic)	Compensatory mild hypercapnia	High HCO₃⁻; Low K⁺; Low Mg²⁺	U_Cl > 20 + Normotensive + Hypocalciuria (DCT NCC defect = 'thiazide diuretic')

Abdominal CT Scan of Autosomal Dominant Polycystic Kidney Disease — **Autosomal Dominant Polycystic Kidney Disease (ADPKD) CT Plate:** Contrast-enhanced abdominal CT scan in Autosomal Dominant Polycystic Kidney Disease (ADPKD) demonstrating massive bilateral nephromegaly with innumerable fluid-filled cortical and medullary cysts replacing normal renal parenchyma, accompanied by concomitant hepatic cysts. View Full Resolution

Winters Formula & Delta-Delta Ratio Worked Mathematical Execution

In any primary metabolic acidosis, chemoreceptors in the carotid bodies and medulla sense [H⁺] and stimulate Kussmaul hyperventilation within minutes. Winters formula calculates the exact expected compensatory arterial carbon dioxide tension: Expected PaCO₂ = (1.5 × [HCO₃⁻]) + 8 ± 2 mmHg. Worked Scenario 1: A patient presents with pH 7.18, PaCO₂ 36 mmHg, and HCO₃⁻ 10 mEq/L. Using Winters formula, Expected PaCO₂ = (1.5 × 10) + 8 ± 2 = 23 ± 2 mmHg (range 21–25 mmHg). Because the patient's actual measured PaCO₂ (36 mmHg) is significantly higher than 25 mmHg, the patient is failing to blow off enough CO₂ and has a mixed metabolic acidosis PLUS concomitant primary respiratory acidosis (signifying impending respiratory muscle fatigue requiring intubation). Conversely, if measured PaCO₂ were 14 mmHg (< 21 mmHg), the patient would have a mixed metabolic acidosis PLUS primary respiratory alkalosis. Next, in any HAGMA, compare the rise in anion gap (ΔAG = AG − 12) to the fall in bicarbonate (ΔHCO₃⁻ = 24 − HCO₃⁻). In a pure HAGMA, ΔAG roughly equals ΔHCO₃⁻ (ratio 1.0–2.0). If ΔAG / ΔHCO₃⁻ < 1.0 (bicarbonate fell more than the AG rose), a concomitant Normal Anion Gap Acidosis (e.g., DKA + diarrhea) is present. If ΔAG / ΔHCO₃⁻ > 2.0 (bicarbonate is higher than expected for the high AG), a concomitant Metabolic Alkalosis (e.g., DKA + severe vomiting) is present.

Salicylate Toxicity Biphasic Acid-Base Pattern vs. Sepsis

Acute salicylate (aspirin) toxicity produces a pathognomonic mixed acid-base signature tested on nearly every board exam. Within the first 1–2 hours of overdose, salicylates directly stimulate the medullary respiratory center in the brainstem, causing tachypnea, hyperventilation, and an early isolated primary respiratory alkalosis (pH > 7.45, low PaCO₂). Over the subsequent 4–12 hours, salicylates uncouple oxidative phosphorylation in the inner mitochondrial membrane, halting aerobic ATP synthesis, accelerating anaerobic glycolysis and lipolysis, and causing lactic acid, ketoacids, and salicylic acid to accumulate in the blood. This generates a mixed primary respiratory alkalosis PLUS a high anion gap metabolic acidosis (HAGMA)—where arterial pH may appear deceptive near 7.40 while both PaCO₂ (< 20 mmHg) and HCO₃⁻ (< 14 mEq/L) are markedly depressed and measured PaCO₂ is below the Winters formula prediction. Treatment of salicylate poisoning requires intravenous sodium bicarbonate infusion to alkalinize both the serum (preventing salicylic acid from crossing the blood-brain barrier) and the urine (pH 7.5–8.0, ion trapping HA → H⁺ + A⁻ in renal tubules to accelerate excretion), with emergent hemodialysis for coma, pulmonary edema, or levels > 100 mg/dL.

Metabolic Alkalosis: Saline-Responsive (Vomiting/NG) vs. Saline-Resistant (Bartter/Gitelman/Conn)

Metabolic alkalosis (pH > 7.45, HCO₃⁻ > 28 mEq/L, with compensatory hypoventilation raising PaCO₂ by 0.7 mmHg per 1 mEq/L rise in HCO₃⁻) is divided by spot urine chloride (U_Cl) into two categories. Saline-responsive (Chloride-depletion) metabolic alkalosis (U_Cl < 20 mEq/L) occurs in gastric vomiting, nasogastric tube suction, and remote/prior loop or thiazide diuretic use. Loss of HCl from the stomach generates serum HCO₃⁻, while intravascular volume depletion activates the RAAS axis (angiotensin II and aldosterone). Because filtered Cl⁻ is depleted, the kidneys avidly reabsorb Na⁺ alongside HCO₃⁻ in the PCT and exchange Na⁺ for H⁺ and K⁺ in the collecting duct—causing paradoxical aciduria and severe hypokalemia that immediately corrects with 0.9% Normal Saline + KCl infusion. Conversely, Saline-resistant metabolic alkalosis (U_Cl > 20 mEq/L) occurs when mineralocorticoid activity or tubular transport is intrinsically abnormal: if the patient is hypertensive, consider Primary Hyperaldosteronism (Conn syndrome), Cushing syndrome, or Liddle syndrome; if the patient is normotensive/hypotensive, differentiate active diuretic abuse from Bartter syndrome (AR defect in thick ascending limb NKCC2 cotransporter; mimics loop diuretics with hypercalciuria and neonatal presentation) and Gitelman syndrome (AR defect in distal convoluted tubule NCC cotransporter; mimics thiazide diuretics with hypocalciuria, severe hypomagnesemia, and adolescent/adult presentation).

Polycystic Kidney Diseases (ADPKD vs. ARPKD) & Renal Cell Carcinoma (VHL & Paraneoplastic Syndromes)

Hereditary cystic nephropathies and primary renal parenchymal malignancies frequently overlap on board exams because both present with flank pain, hematuria, hypertension, and palpable abdominal masses—and notably, von Hippel-Lindau (VHL) syndrome bridges both multiple bilateral renal cysts and multifocal clear cell renal cell carcinoma. Differentiating adult-onset Autosomal Dominant Polycystic Kidney Disease (ADPKD) from neonatal Autosomal Recessive Polycystic Kidney Disease (ARPKD) and recognizing the paraneoplastic hallmarks of Renal Cell Carcinoma (RCC) are high-yield nephrology requirements.

Renal Cystic / Neoplastic Entity	Genetic Defect & Cell of Origin	Histopathology / Imaging Hallmark	Classic Systemic Associations	First-Line Management
ADPKD (Adult Polycystic)	AD PKD1 (chr 16, 85%) or PKD2 (chr 4); tubular cilia polycystin	Massive bilateral cortical & medullary cysts on US/CT	Hepatic cysts, Circle of Willis berry aneurysms, MVP, diverticulosis, HTN	ACEi/ARB for HTN; Tolvaptan (V₂ antagonist) to slow cyst growth; MRA if FHx SAH
ARPKD (Infantile Polycystic)	AR PKHD1 (chr 6); collecting duct fibrocystin	Bilateral enlarged echogenic kidneys with radial microcysts	Oligohydramnios → Potter sequence; congenital hepatic fibrosis & portal HTN	Neonatal respiratory support, dialysis, combined kidney-liver transplant
Clear Cell RCC (75%)	VHL deletion (chr 3p) → ↑ HIF → ↑ VEGF; Proximal tubule	Golden-yellow mass; polygonal clear cells (lipid/glycogen); invades renal vein	Left varicocele; Paraneoplastic: EPO, PTHrP, Renin, ACTH, Stauffer syndrome	Partial/radical nephrectomy; Metastatic: Pembrolizumab/Nivolumab + Axitinib/Cabozantinib
Papillary RCC (10–15%)	Activating MET proto-oncogene, trisomy 7/17; Proximal tubule	Papillary fronds with fibrovascular cores, foamy macrophages, psammoma bodies	Chronic hemodialysis (acquired cystic disease); often bilateral and multifocal	Partial or radical nephrectomy; cabozantinib (MET/VEGFR inhibitor) if metastatic
Renal Oncocytoma (Benign)	Collecting duct intercalated cell	Well-circumscribed mahogany-brown tumor with central stellate scar; eosinophilic cells packed with mitochondria	Painless hematuria; mimics RCC on CT so often resected	Nephron-sparing partial nephrectomy or active surveillance
Renal Angiomyolipoma (Benign)	TSC1 (hamartin) / TSC2 (tuberin) mutation; mesenchymal	Fat-attenuating renal mass on CT; thick-walled blood vessels, smooth muscle, adipose tissue	Tuberous Sclerosis (ash-leaf spots, facial angiofibromas, cardiac rhabdomyoma); Wunderlich hemorrhage	Everolimus (mTOR inhibitor) or selective arterial embolization if > 4 cm

Histopathology of Clear Cell Renal Cell Carcinoma — **Clear Cell Renal Cell Carcinoma Histopathology Plate:** H&E section of clear cell renal cell carcinoma illustrating nests of neoplastic proximal tubular epithelial cells with optically clear cytoplasm (resulting from dissolution of abundant intracellular glycogen and neutral lipids during processing) separated by a delicate branching chicken-wire capillary vasculature. View Full Resolution

ADPKD (PKD1/PKD2, Berry Aneurysms, Tolvaptan) vs. ARPKD (PKHD1, Potter Sequence)

Autosomal Dominant Polycystic Kidney Disease (ADPKD) results from germline mutations in PKD1 on chromosome 16 (85% of cases, encoding polycystin-1; progresses to ESRD ~age 54) or PKD2 on chromosome 4 (15%, encoding polycystin-2; milder, ESRD ~age 74). Primary cilia defects in tubular epithelial cells drive relentless proliferation and fluid secretion, replacing both kidneys with hundreds of large cortical and medullary cysts. Patients remain asymptomatic until age 30–50, when they present with gross hematuria (from cyst rupture or nephrolithiasis), flank pain, palpable bilateral ballotable abdominal masses, and renin-mediated hypertension. High-yield extrarenal manifestations include hepatic cysts (most common extrarenal feature, 70%), intracranial saccular ('berry') aneurysms at the circle of Willis (8–10%, screen with MRA if positive family history of subarachnoid hemorrhage or high-risk occupation), mitral valve prolapse, colonic diverticulosis, and abdominal wall hernias. Renal ultrasound is the initial screening test; ACE inhibitors/ARBs are first-line for hypertension, and tolvaptan (selective vasopressin V₂ receptor antagonist that lowers intracellular cAMP in collecting duct cysts) slows cyst growth and GFR decline. Conversely, ARPKD is caused by mutations in PKHD1 on chromosome 6 (encoding fibrocystin) and presents in neonates/infants with bilaterally enlarged echogenic kidneys containing radially oriented collecting duct microcysts. Fetal oligohydramnios triggers Potter sequence (pulmonary hypoplasia, limb deformities, flattened facies), while survivors inevitably develop congenital hepatic fibrosis and portal hypertension.

Renal Cell Carcinoma: Clear Cell (VHL Chr 3p), Left Varicocele & Paraneoplastic Syndromes

Renal Cell Carcinoma (RCC) originates from the proximal convoluted tubule epithelium and is most prevalent in men aged 50–70. Major risk factors are cigarette smoking, obesity, hypertension, and acquired cystic disease of dialysis. The classic clinical triad—painless hematuria, flank pain, and a palpable flank mass—occurs in only 10% of patients and indicates advanced disease. A crucial anatomical board clue is an acute, non-reducing left-sided varicocele that fails to empty when the patient lies supine: because the left gonadal (testicular) vein drains perpendicularly into the left renal vein (whereas the right gonadal vein drains directly into the IVC), a left-sided RCC invading and occluding the left renal vein obstructs left pampiniform plexus venous return. Histologically, Clear Cell RCC (70–80%) exhibits polygonal cells with clear lipid- and glycogen-rich cytoplasm caused by sporadic or germline deletion of the VHL tumor suppressor gene on chromosome 3p. Loss of VHL prevents ubiquitylation of hypoxia-inducible factor (HIF-1α/2α), driving constitutive transcription of VEGF, PDGF, and EPO. RCC is termed the 'internist's tumor' due to its five classic paraneoplastic syndromes: Polycythemia (ectopic EPO), Hypercalcemia (ectopic PTHrP or osteolytic prostaglandins), Secondary Hypertension (ectopic renin), Cushing Syndrome (ectopic ACTH), and Stauffer Syndrome (non-metastatic IL-6-mediated reversible hepatic dysfunction with elevated ALP/bilirubin/PT that resolves after nephrectomy).

RCC Subtypes (Papillary, Chromophobe) vs. Oncocytoma vs. Angiomyolipoma & Therapy

Beyond clear cell RCC, Papillary RCC (10–15%) arises from proximal tubules, is frequently multifocal and bilateral, and is associated with long-term hemodialysis and activating MET proto-oncogene mutations (trisomy 7 and 17), displaying fibrovascular cores lined by neoplastic cells with psammoma bodies and foamy macrophages. Chromophobe RCC (5%) originates from intercalated cells of the collecting duct, features pale eosinophilic cells with a perinuclear halo ('plant-like' raisinoid nuclei), and carries the best prognosis among RCC subtypes. Two benign renal masses must be distinguished: Renal Oncocytoma (arising from collecting duct intercalated cells, showing a central stellate scar on CT and sheets of deeply eosinophilic cells packed with abundant normal mitochondria) and Renal Angiomyolipoma (a benign hamartoma composed of blood vessels, smooth muscle, and mature fat strongly associated with Tuberous Sclerosis [TSC1/TSC2]). Localized RCC (Stage I–III) is cured by partial (nephron-sparing) or radical nephrectomy. Because RCC is radioresistant and chemoresistant, metastatic RCC is treated with immune checkpoint inhibitors (nivolumab + ipilimumab, or pembrolizumab) combined with VEGF receptor tyrosine kinase inhibitors (axitinib, cabozantinib, sunitinib, pazopanib).

COMLEX / OMM Integration NBOME High-Yield Correlate

Renal & Ureteral Autonomics, Psoas Mechanics, Chapman Points & Fluid Overload OMT

Sympathetic Innervation (Kidneys vs. Ureters vs. Bladder): Sympathetic preganglionic neurons supplying the kidneys originate at T10–T11, travel via the least splanchnic nerve, and synapse in the aorticorenal and superior mesenteric ganglia. The upper ureters receive sympathetic fibers from T10–T11, whereas the lower ureters and urinary bladder fundus receive sympathetic outflow from T12–L2 via the lumbar splanchnic nerves and inferior mesenteric / hypogastric plexus. Acute nephrolithiasis produces an intense viscerosomatic reflex along T10–L2 ipsilaterally; elevated sympathetic tone constricts renal arterioles (activating RAAS) and induces ureterospasm.
Parasympathetic Innervation Watershed: The vagus nerve (CN X) provides parasympathetic innervation to the kidneys and upper ureters, whereas the pelvic splanchnic nerves (S2–S4) innervate the lower ureters and urinary bladder detrusor muscle.
Anterior & Posterior Chapman Reflex Points: The kidney anterior Chapman point lies 1 inch superior and 1 inch lateral to the umbilicus, while the urinary bladder anterior Chapman point is located directly on the periumbilical region (and the urethra/trigone along the superior margin of the pubic symphysis). Posterior Chapman points are located between the transverse processes of T12 and L1 for the kidneys, and over the transverse process of L2 for the bladder.
Psoas Syndrome & OMT Contraindications: Because the ureter courses directly anterior to the psoas major muscle (whose tenderpoint lies 2 inches medial and 1 inch inferior to the ASIS, treated in F S_TowardR_Away), an impacted ureteral stone triggers acute ipsilateral psoas spasm (flexed posture, positive Thomas test, L1–L2 Type II dysfunction). While paraspinal inhibition at T10–L2 and psoas counterstrain reduce ureterospasm, lymphatic pump techniques are strictly contraindicated in anuric/oliguric Stage G5 CKD or uncompensated volume overload due to risk of precipitating acute flash pulmonary edema.

Board Traps & Common Distractors

Infected Obstructing Ureteral Stone (Obstructive Pyelonephritis): A patient with a ureteral calculus who presents with fever, rigors, leukocytosis, pyuria, or hemodynamic instability has a life-threatening urological surgical emergency; antibiotics cannot penetrate an obstructed collecting system—perform immediate emergent decompression via retrograde ureteral stenting or percutaneous nephrostomy tube (do NOT perform shock wave lithotripsy acutely!).
Dietary Calcium Restriction Trap in Calcium Oxalate Stones: Never instruct a patient with recurrent calcium oxalate nephrolithiasis to restrict dietary calcium intake! Low intestinal calcium leaves dietary oxalate unbound in the gut lumen, increasing colonic oxalate absorption and worsening hyperoxaluria and stone formation; prescribe normal dietary calcium, low sodium, high fluid intake, and a thiazide diuretic.
Crohn Disease & Enteric Hyperoxaluria: Patients with ileal Crohn disease or small bowel resection develop fat malabsorption; unabsorbed intraluminal fatty acids bind intestinal calcium (saponification), leaving free oxalate to be hyperabsorbed in the colon and precipitating recurrent calcium oxalate kidney stones.
ESA Hemoglobin Target Trap in CKD: In Anemia of CKD, always replete iron stores before starting epoetin alfa or darbepoetin alfa, and never titrate hemoglobin above 11.5 g/dL (targeting > 13 g/dL increases stroke, MI, and thromboembolism mortality).
New Left-Sided Varicocele in an Older Man: Because the left gonadal vein drains at a 90-degree angle into the left renal vein, an acute left-sided varicocele that fails to collapse in the supine position mandates an abdominal CT to rule out a left Renal Cell Carcinoma invading the left renal vein.
Gadolinium & Nephrogenic Systemic Fibrosis (NSF): Avoid Group I gadolinium-based MRI contrast agents in patients with severe CKD (eGFR < 30 mL/min/1.73 m²) or dialysis dependence due to the risk of irreversible Nephrogenic Systemic Fibrosis (woody cutaneous induration and joint contractures mimicking scleroderma).

Previous Chapter • Vol 2: Clinical Ch. 29

Malabsorption, Colorectal Polyps & Colon Cancer

Vol 2: Clinical Ch. 31 • Next Chapter

Calcium Disorders, Pituitary Pathology & MEN Syndromes

Table of Contents (105 Chapters) Volume 2: Organ System Clinical Pathology • Chapter 30 of 60